¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦31Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) : 2022-05-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦31Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) : 2022-05-20
±³À°ÀÏÀÚ : 2022-05-20
±³À°Àå¼Ò : °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B ¿Ü 1°³·ë  
±³À°ÁÖÁ¦ : Á¦31Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑ¿µ»óÀÇÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ  
´ã´çÀÚ : ÁÖÇýÁ¤
¿¬¶ôó : 02-465-9070  
À̸ÞÀÏ : office@intervention.or.kr      
±³À°Á¾·ù : ¿µ»óÀÇÇаúÀÇ»çÇÐ
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 4Á¡  
Áö¿ª : °æ»óºÏµµ
±³À°½Ã°£ : 6 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 120,000¿ø      
ºñ°í »çÀüµî·Ï-Á¤È¸¿ø50000¿ø, Àü¹®ÀÇ100000¿ø, Àü°øÀÇ(¿¬È¸ºñ³³ºÎÀÚ)¹«·á, Àü°øÀǹװøº¸ÀÇ 30000¿ø, ÁØȸ¿ø¹×±âŸ 50000¿ø/ÇöÀåµî·Ï-Á¤È¸¿ø70000¿ø, Àü¹®ÀÇ120000¿ø, Àü°øÀÇ(¿¬È¸ºñ³³ºÎÀÚ)¹«·á, Àü°øÀǹװøº¸ÀÇ 50000¿ø, ÁØȸ¿ø¹×±âŸ 70000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:00~13:07 Factors for successful transvenous retrograde thoracic duct cannulation  ±èÇüõ(°Ç¾çÀÇ´ë) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:07~13:10 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:10~13:17 To evaluate technical success and safety of a planned percutaneous transhepatic approach (PPTA) to the thoracic duct  Á¤±¸¼º(õ¾ÈÃ湫º´¿ø) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:17~13:20 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:20~13:27 Efficacy and Safety of Large-Bore Uncovered Stents for Malignant Superior Vena Cava Syndrome  ÃÖ»ó¸²(Áß¾Ó´ëÇб³ ±¤¸íº´¿ø) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:27~13:30 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:30~13:37 Deep learning quantification of degree of AVF stenosis and prediction of 6months primary patency based on AVF shunt sound  ¹®¼º¸ð(¿¬¼¼ÀÇ´ë) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:37~13:40 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:40~13:47 The Usefulness of Catheter Length Prediction Formula Using Only the Anteroposterior Chest Radiograph and Wireless Ultrasound System in Bedside PICC Insertion: A Single Center Experience for Patients in COVID-19 Isolation Ward  ¹Ú¼ºÁØ(°í·ÁÀÇ´ë) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:47~13:50 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:50~13:57 Effectiveness of two sessions of catheter-directed sclerotherapy for ovarian endometrioma  ½ÅÁöÈÆ(¿ï»êÀÇ´ë) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:57~14:00 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 14:00~14:15 Vessel preparation: when and how  ±ÇÁØÈ£(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 14:15~14:30 Drug coated balloons: are there any differences?  ±è¹Î¿í(º¸¶ó¸Åº´¿ø) 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 14:30~14:45 Stents: what are the remaining roles of stents in SFA in an era of drug technology  Á¶¼ö¹ü(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 14:45~15:00 BTK angioplasty for limb salvage: how I do it  ¹Ú»ó¿ì(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 15:00~15:15 Is DVA a viable option for &quotno option" limb or &quotdesert foot"  ±Ç¿äÇÑ(¾ÆÁÖÀÇ´ë) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 15:15~15:20 Discussion  () 
È޽Ġ05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 15:20~15:40 Coffee break  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 15:40~15:55 Clinical evaluation of varicose vein patients  Á¶ÁøÇö(°­µ¿°æÈñ´ëº´¿ø) 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 15:55~16:10 Radiological evaluation of varicose vein patients  ±Ç·Á¹Î(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 16:10~16:25 Update in varicose vein intervention  ÀÌÀ±ÇÐ(¼­¿ï¼±Ç÷°üÅëÁõ¼¾ÅÍ) 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 16:25~16:45 Various devices for endovenous procedure for varicose vein (case based)  È²ÁøÈ£(°Ç±¹ÀÇ´ë) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 16:45~16:50 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 16:50~17:20 What¡¯s new  ½ÉÀçÇö, ÀÌ¿ì¶÷(Boston, COOK) 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 205+206 13:00~13:07 Catheter-directed sclerotherapy versus Surgical excision with subsequent Dienogest therapy for the treatment of ovarian endometrioma: Propensity score analyses of short-term outcomes  ÀÌÀçȯ(ºÐ´ç¼­¿ï´ëÇб³º´¿ø) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:07~13:10 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 205+206 13:10~13:17 Modified surgical drain-guided percutaneous catheter drainage for postoperative fluid collection in inaccessible locations  ÀÌÇü³²(¼øõÇâÀÇ´ë) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:17~13:20 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 205+206 13:20~13:27 Pathologic response of single hepatocellular carcinoma treated with balloon-occluded transcatheter arterial chemoembolization  ±èÁöÈÆ(¿ï»êÀÇ´ë) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:27~13:30 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 205+206 13:30~13:37 Percutaneous nephrostomy for complex renal stone : Percutaneous renal access behind a stone  ¾ÈÀç°æ(°æ»óÀÇ´ë) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:37~13:40 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 205+206 13:40~13:47 Comparison of technical feasibility and clinical outcomes between 6Fr and 8Fr Double J Stents for Ureteral Obstruction  ¿ÀâÈÆ(°í·ÁÀÇ´ë) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:47~13:50 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 205+206 13:50~13:57 Outcomes of percutaneous transhepatic treatment for bile duct stones a multicenter retrospective study in 2431 patients  Á¤±Ô½Ä(¿ï»êº´¿ø) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:57~14:00 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 205+206 14:00~14:20 Hemodynamics of HCC  Á¤Áø¿í(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 205+206 14:20~14:40 Drug preparation - lipiodol and embolic materials  ±èȿö(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 205+206 14:40~15:00 Superive TACE  ÀÌÀÎÁØ(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 205+206 15:00~15:20 Arterial anatomy - What to know during TACE  ±è°æ¹Î(¿¬¼¼ÀÇ´ë) 
È޽Ġ05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 205+206 15:20~15:40 Coffee break  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦31Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) : 2022-05-20""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑÁ¶Çöº´ÇÐȸ Quality of life as a treatment goal in schizophrenia : 2022-05-20
´ÙÀ½±Û (¿Â¶óÀÎ) 2022³â 5¿ù ´ëÇÑÇÙÀÇÇÐȸ ¿ù·ÊÁý´ãȸ ¹× Ãá°è¿µÈ£³²Áý´ãȸ : 2022-05-20
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
257 ¼­¿ï »ï¼º¼­¿ïº´¿ø 2018 »ï¼º ¾È°ú ±Ý¿äÁý´ãȸ : 2018-09-14 0 675 2018-07-28
256 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø 2018 ÀÇ·áÇöÀå¿¡¼­ ¸¸³ª´Â ¾à¹°¾Ë·¹¸£±â : 2018-09-14 0 832 2018-07-28
255 ¼­¿ï »ï¼º¼­¿ïº´¿ø ¾ÓÄÚ¸£¼­¿ï 2018 : 2018-09-14 0 555 2018-07-28
254 ¼­¿ï ¼­¿ïƯº°½ÃÀÇ»çȸ °­ÀÇ(Àú½ÅÀåÄ¡·á, ¹æ»ç¼±Ä¡·á) : 2018-09-13 0 1,166 2018-07-28
253 ¼­¿ï °í·Á´ëÇб³±¸·Îº´¿ø 1) Á¡¸·Áúȯ 2) ÇǺΠ¸é¿ªÇÐ : 2018-09-13 0 840 2018-07-28
252 ¼­¿ï »ï¼º¼­¿ïº´¿ø ¾ÓÄÚ¸£¼­¿ï 2018 : 2018-09-13 0 451 2018-07-28
251 ºÎ»ê ´ëÇÑ°£ÇÐȸ ºÎ»ê¿ï»ê°æ³²Áöȸ Áý´ãȸ : 2018-09-13 0 600 2018-07-28
250 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø ÀӽŠ¹× ¼öÀ¯±â°£ Áß ¾à¹° Ä¡·á : 2018-09-12 0 667 2018-07-28
249 Ãæ³² ´ëÇÑ°¡Á¤ÀÇÇÐȸ °»³â±â È£¸£¸ó Ä¡·áÀÇ ÃÖ½ÅÁö°ß : 2018-09-12 0 604 2018-07-28
248 ¼­¿ï »ï¼º¼­¿ïº´¿ø ¾ÓÄÚ¸£¼­¿ï 2018 : 2018-09-12 0 686 2018-07-28
247 ÀÎõ ÀÎÇÏ´ëÇб³º´¿ø ³ì³»ÀåȯÀÚÀÇ ¾à¹°Ä¡·á : 2018-09-11 0 406 2018-07-28
246 ÃæºÏ 2018³â ÃæºÏ´ëÇб³º´¿ø ºñ´¢ÀÇÇаú ¿¬¼ö°­Á : 2018-09-11 0 674 2018-07-28
245 ¼­¿ï ´ëÇѾȰúÇÐȸ ¼­¿ï ³²ºÎ Áöȸ ¿¬¼ö ±³À° : 2018-09-10 0 709 2018-07-28
244 ¼­¿ï Á¦ 1ȸ °­ºÏ»ï¼ºº´¿ø ¼Ò¾Æû¼Ò³â°ú °³¿øÀÇ ¿¬¼ö°­Á : 2018-09-09 0 765 2018-07-28
243 ¼­¿ï 2018³â ´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸ ¼Ò¾Æû¼Ò³â ¿µ¾ç ½ÉÆ÷Áö¾ö : 2018-09-09 0 767 2018-07-28
1391 | 1392 | 1393 | 1394 | 1395 | 1396 | 1397 | 1398 | 1399 | 1400
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷